La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
MacroGenics Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Scott Koenig
Directeur général
US$3.7m
Rémunération totale
| Pourcentage du salaire du PDG | 19.0% |
| Durée du mandat du directeur général | 23yrs |
| Propriété du PDG | 2.1% |
| Durée moyenne d'occupation des postes de direction | 7.6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.3yrs |
Mises à jour récentes de la gestion
Recent updates
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$136m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | US$4m | US$705k | -US$9m |
| Sep 30 2023 | n/a | n/a | US$50m |
| Jun 30 2023 | n/a | n/a | US$7m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$5m | US$673k | -US$120m |
| Sep 30 2022 | n/a | n/a | -US$191m |
| Jun 30 2022 | n/a | n/a | -US$219m |
| Mar 31 2022 | n/a | n/a | -US$217m |
| Dec 31 2021 | US$5m | US$651k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$146m |
| Jun 30 2021 | n/a | n/a | -US$129m |
| Mar 31 2021 | n/a | n/a | -US$136m |
| Dec 31 2020 | US$3m | US$656k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$158m |
| Jun 30 2020 | n/a | n/a | -US$167m |
| Mar 31 2020 | n/a | n/a | -US$152m |
| Dec 31 2019 | US$5m | US$590k | -US$152m |
| Sep 30 2019 | n/a | n/a | -US$166m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$5m | US$599k | -US$171m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$34m |
| Mar 31 2018 | n/a | n/a | -US$32m |
| Dec 31 2017 | US$3m | US$554k | -US$20m |
Rémunération vs marché: La rémunération totale de Scott ($USD 3.71M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.54M ).
Rémunération et revenus: La rémunération de Scott a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Scott Koenig (72 yo)
23yrs
Titularisation
US$3,705,825
Compensation
Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 23yrs | US$3.71m | 2.07% $ 4.1m | |
| Senior VP | 16.3yrs | US$1.58m | 0.27% $ 546.9k | |
| Senior VP of Clinical Development & Chief Medical Officer | 4.2yrs | US$1.75m | 0.016% $ 31.3k | |
| Chief Operating Officer | 2.6yrs | US$1.92m | 0.062% $ 124.1k | |
| Senior Vice President of Technical Operations | 1.8yrs | US$1.88m | 0.013% $ 26.5k | |
| Senior VP of Research & Chief Scientific Officer | 8yrs | US$2.29m | 0.16% $ 321.9k | |
| Senior VP | 7.3yrs | pas de données | 0% $ 0 | |
| VP, Controller & Treasurer | 20.9yrs | pas de données | 0.0099% $ 19.8k |
7.6yrs
Durée moyenne de l'emploi
61.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de MGNX est chevronnée et expérimentée (ancienneté moyenne 7.5 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 23yrs | US$3.71m | 2.07% $ 4.1m | |
| Independent Director | 11yrs | US$160.75k | 0.0072% $ 14.3k | |
| Independent Director | 3.6yrs | US$152.00k | 0.0072% $ 14.3k | |
| Independent Director | 19.9yrs | US$147.63k | 0.060% $ 119.9k | |
| Independent Director | 1.7yrs | US$318.32k | 0.0072% $ 14.3k | |
| Independent Chairman of the Board | 2.3yrs | US$180.13k | 0.0072% $ 14.3k | |
| Independent Director | 1.7yrs | US$335.41k | 0.0072% $ 14.3k | |
| Independent Director | 7.7yrs | US$167.63k | 0.0072% $ 14.3k | |
| Independent Director | 6.8yrs | US$167.21k | 0.0072% $ 14.3k | |
| Independent Director | 7.7yrs | US$135.75k | 0.0072% $ 14.3k |
7.3yrs
Durée moyenne de l'emploi
66yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de MGNX sont considérés comme expérimentés (ancienneté moyenne 7.2 ans).